ArticleNeuro-oncology2023

Reply to Di Nunno et al. concerning objective response rates targets for recurrent glioblastoma clinical trials: Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma.

Benjamin M Ellingson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.